Methodology

All entries for: Imbria Pharmaceuticals

June 18, 2026

Imbria Pharmaceuticals

Orphan Drug Designation

treatment of symptomatic nonobstructive hypertrophic cardiomyopathy

Disease Area: Rare Diseases